Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Spratt

Showing results (31-40 of 497) with videos related to

Pageof 50
Sort By:
JAMA Oncology|December 19, 2024
Assessing the Risk of Radiation Myelitis in Hypofractionated Stereotactic Body Radiation Therapy-Tolerance Is in the Eye of the BeholderEvangelia Katsoulakis, Daniel E Spratt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent?Daniel E Spratt, Nicholas Szerlip
International Journal of Radiation Oncology, Biology, Physics|February 25, 2026
Continuing the Focal FallacyJonathan Shoag, Daniel E Spratt
Brachytherapy|August 31, 2013
Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patientsDaniel E Spratt, Michael J Zelefsky
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based AlternativeAngela Y Jia, Daniel E Spratt
European Urology|November 13, 2016
Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. A Step Forward in the Era of Functional Imaging?: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field DesignDaniel E Spratt, Michael J Zelefsky
The Lancet. Oncology|October 3, 2024
A step closer to the use of [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancerAngela Y Jia, Daniel E Spratt
International Journal of Radiation Oncology, Biology, Physics|June 18, 2019
Long-Term Benefits of Dose-Escalation in Localized Prostate CancerDaniel E Spratt, Jeff M Michalski
Prostate Cancer and Prostatic Diseases|December 16, 2022
Radiotherapy in patients with node-positive prostate cancer after radical prostatectomyAngela Y Jia, Daniel E Spratt
The Lancet. Oncology|October 2, 2025
Revisiting prostate cancer active surveillance candidacyDaniel E Spratt, Edward M Schaeffer
Pageof 50

Showing results (31-40 of 497) with videos related to

Sort By:
Pageof 50
JAMA Oncology|December 19, 2024
Assessing the Risk of Radiation Myelitis in Hypofractionated Stereotactic Body Radiation Therapy-Tolerance Is in the Eye of the BeholderEvangelia Katsoulakis, Daniel E Spratt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent?Daniel E Spratt, Nicholas Szerlip
International Journal of Radiation Oncology, Biology, Physics|February 25, 2026
Continuing the Focal FallacyJonathan Shoag, Daniel E Spratt
Brachytherapy|August 31, 2013
Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patientsDaniel E Spratt, Michael J Zelefsky
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based AlternativeAngela Y Jia, Daniel E Spratt
European Urology|November 13, 2016
Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. A Step Forward in the Era of Functional Imaging?: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field DesignDaniel E Spratt, Michael J Zelefsky
The Lancet. Oncology|October 3, 2024
A step closer to the use of [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancerAngela Y Jia, Daniel E Spratt
International Journal of Radiation Oncology, Biology, Physics|June 18, 2019
Long-Term Benefits of Dose-Escalation in Localized Prostate CancerDaniel E Spratt, Jeff M Michalski
Prostate Cancer and Prostatic Diseases|December 16, 2022
Radiotherapy in patients with node-positive prostate cancer after radical prostatectomyAngela Y Jia, Daniel E Spratt
The Lancet. Oncology|October 2, 2025
Revisiting prostate cancer active surveillance candidacyDaniel E Spratt, Edward M Schaeffer
Pageof 50